Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
93% overall response and 76% complete response rates with median progression-free survival…
Lyell Immunopharma to Participate in the H.C. Wainwright HCW@Home Series
June 23, 2025 17:00 ET | Source: Lyell Immunopharma, Inc SOUTH SAN…
